恒瑞医药涨近3% 富马酸泰吉利定注射液临床试验获批

Core Viewpoint - Heng Rui Medicine (600276) has seen a nearly 3% increase in stock price, currently trading at 72.35 HKD, following the announcement of clinical trial approval for its drug, Fumaric Acid Tegeline Injection, by the National Medical Products Administration of China [1] Group 1: Company Developments - On November 17, Heng Rui Medicine announced that it received the clinical trial approval notice for Fumaric Acid Tegeline Injection from the National Medical Products Administration [1] - Fumaric Acid Tegeline Injection is a μ-opioid receptor (MOR) biased small molecule agonist, set to be approved for domestic market launch in January 2024, marking it as China's first independently developed Class 1 opioid analgesic innovation drug [1] - The company has invested approximately 200 million RMB in the research and development of Fumaric Acid Tegeline Injection to date [1] Group 2: Market Context - The drug has a comparable product, Oliceridine (brand name: Olinvyk), developed by Trevena, which was approved for sale in the United States in 2020 [1] - Jiangsu Enhua Pharmaceutical Co., Ltd. has obtained exclusive licensing from Trevena for Oliceridine, which was approved for sale in China in May 2023, although no sales data has been reported yet [1]